Literature DB >> 25792473

Clinical significance of the VEGF level in urinary bladder carcinoma.

Monica Sankhwar1, Satya Narayan Sankhwar1, Amar Abhishek1, Singh Rajender2.   

Abstract

OBJECTIVE: To investigate the correlation of Vascular Endothelial Growth Factor (VEGF) and micro-vessel density (MVD) with urinary bladder tumor and its stage.
MATERIAL AND METHODS: The study was conducted between January 2010 and December 2012. The study included screening of 122 patients at elevated risk for bladder cancer, of which 35 patients were finally enrolled in the study. Diagnosis was made on the basis of urine cytology, radiological investigation (ultrasound KUB, and CT-scan) and histopathology. Thirty-five normal cancer-free individuals were enrolled as controls. Human VEGF levels were measured using an enzyme linked immunoassay and protein content (pg/mg protein) by Lowry method. SPSS for Windows version 10.0.7 (SPSS, Chicago, IL, USA) was used for statistical analysis of the data.
RESULTS: Mean urine VEGF level in the cases was significantly higher in comparison to the control group. There was a direct correlation between VEGF level and tumor stage. Mean urine VEGF values were minimum in the control group (22.75 ± 15.41 pg/mg creatinine) and maximum in stage IV patients (180.15 ± 75.93 pg/mg creatinine). Tissue VEGF levels also showed a similar trend of increase with increase in stage. Urine VEGF level also showed a correlation with tissue VEGF level. Similarly, MVD showed a significant increase with increase in tumor stage. DISCUSSION: A correlation between bladder cancer and MVD and VEGF suggest that the latter can serve as markers for therapeutic guidance. This is the first study from India on clinical and pathological correlation among urine VEGF, tumor tissue VEGF levels, and Micro Vessel Density (MVD) in urinary bladder cancer patients.

Entities:  

Keywords:  Angiogenesis; MVD; VEGF; urinary bladder cancer; urothelial carcinoma

Mesh:

Substances:

Year:  2015        PMID: 25792473     DOI: 10.3233/CBM-150478

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  5 in total

1.  An Integrated Bioinformatics Analysis towards the Identification of Diagnostic, Prognostic, and Predictive Key Biomarkers for Urinary Bladder Cancer.

Authors:  Michail Sarafidis; George I Lambrou; Vassilis Zoumpourlis; Dimitrios Koutsouris
Journal:  Cancers (Basel)       Date:  2022-07-10       Impact factor: 6.575

Review 2.  Deciphering the Roles of Thiazolidinediones and PPARγ in Bladder Cancer.

Authors:  Melody Chiu; Lucien McBeth; Puneet Sindhwani; Terry D Hinds
Journal:  PPAR Res       Date:  2017-02-28       Impact factor: 4.964

Review 3.  Emerging therapeutic agents for genitourinary cancers.

Authors:  Kevin Zarrabi; Azzam Paroya; Shenhong Wu
Journal:  J Hematol Oncol       Date:  2019-09-04       Impact factor: 17.388

4.  Interleukin-35 as a predictor of prostate cancer in patients undergoing initial prostate biopsy.

Authors:  Chenchao Zhou; Jun Zhang; Ye Chen; Hao Wang; Jianquan Hou
Journal:  Onco Targets Ther       Date:  2017-07-14       Impact factor: 4.147

Review 5.  Current perspectives on novel systemic therapeutic agents beyond immune checkpoint inhibition in metastatic urothelial carcinoma.

Authors:  Hoon Choi; Jae Young Park; Jae Hyun Bae; Bum Sik Tae
Journal:  Transl Cancer Res       Date:  2020-10       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.